La cadena de opciones muestra datos clave de las opciones de acciones de HCA Healthcare a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para HCA Healthcare..

HCA Healthcare (NYSE:HCA) Bolsa, Cadena de Opciones

HCA Healthcare

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.

HCA Healthcare Inc

HSBC MSCI CHINA A UCITS ETF USD ACC

Hony Capital Acquisition Corp

HSBC MSCI CANADA UCITS ETF

HOLDING CO ADMIE IPTO by Holding Co Admie Ipto SA

Holding Co ADMIE (IPTO) SA

Huachen AI Parking Management Technology Holding Co Ltd

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

Health Catalyst Inc

TD Cowen analyst Gary Taylor maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Buy and lowers the price target from $450 to $440.

News

Price Target

Analyst Ratings

TD Cowen Maintains Buy on HCA Healthcare, Lowers Price Target to $440

Keybanc analyst Matthew Gillmor maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and lowers the price target from $475 to $420.

Keybanc Maintains Overweight on HCA Healthcare, Lowers Price Target to $420

Oppenheimer analyst Michael Wiederhorn maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Outperform and raises the price target from $390 to $400.

Oppenheimer Maintains Outperform on HCA Healthcare, Raises Price Target to $400

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Friday.
U.S. stocks settled mixed on Friday, with the Nasdaq Composite surging to an all-time high during the session.
Tech stocks provided a boost to the market ahead of their upcoming quarterly earnings. Shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAZN#NASDAQ">AMAZN</a>) settled higher on Friday.
Both the Dow Jones and S&amp;P 500 ended a six-week winning streak, falling around 1% and 2.7%, respectively. The Nasdaq recorded gains for the seventh straight week, gaining nearly 0.2% last week.
Shares of HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) fell around 9% on Friday after the company reported weaker-than-expected third-quarter financial results. Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) shares fell around 4% after the company reported third-quarter earnings.
On the economic data front, the University of Michigan consumer sentiment for the U.S. rose to 70.5 in October compared to a preliminary reading of 68.9. U.S. durable goods orders fell by 0.8% to $284.8 billion in September compared to a revised 0.8% fall in August.
Most sectors on the S&amp;P 500 closed on a negative note, with financials, real estate, and utilities stocks recording the biggest losses on Friday. However, information technology and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 260 points to 42,114.40 on Friday. The S&amp;P 500 fell 0.03% to 5,808.12, while the Nasdaq Composite climbed 0.56% at 18,518.61 during Friday's session.
Investors are awaiting earnings results from ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>), and Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 58.9, the index remained in the &#8220;Greed&#8221; zone on Friday, versus a prior reading of 61.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41545103/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Equities

Pre-Market Outlook

Markets

Trading Ideas

AMAZN

NVDA

Nasdaq Surges To Fresh Highs As Nvidia, Meta And Amazon Register Gains: Fear Index Remains In 'Greed' Zone

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) shares plummeted 25.95% after the company reported <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener">worse-than-expected results</a>. Several analysts also cut the <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) stock tumbled 20.21% after it reported mixed third-quarter results and cut its <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener">FY24 EPS below estimates</a>. Multiple analysts cut the <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) shares dipped 15.97% after the company reported <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Analysts trimmed the <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price target</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock lost 14.71% last week. Several healthcare stocks and hospital operators fell in possible sympathy with HCA Healthcare, which declined on Q3 earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stock fell 14.33% last week after the company reported <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener">Q3 financial results</a>.</li>
<li>HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock fell 12.51% after reporting <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 financial results</a>. The company expects Hurricane Helene&#8217;s impact to continue in 2025.</li>
<li>TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) stock lost 11.48% last week as homebuilding stocks <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener">took a beating</a> due to Hurricane Milton&#8217;s impact.</li>
<li>Carlisle Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) fell 11.45% last week on <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 performance</a>.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock declined 11.34% after it reported <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Some analysts trimmed the <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Comfort Systems USA, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock declined 11.27% after the company reported <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 sales results</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41560908/tesla-li-auto-and-microstrategy-are-among-top-10-large-cap-gainers-last-week-oct-21-oct-25-are-the">Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
</ul>

Large Cap

Movers

ICLR

Genuine Parts Company, Universal Health Services, And TopBuild Are Among Top 10 Large Cap Losers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week&#8217;s pivotal earnings releases from <a href="https://www.benzinga.com/topic/magnificent-7">five of the &#8220;Magnificent Seven&#8221; stocks.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) will all report quarterly earnings between Oct. 29 and Oct. 31.
Combined, nearly 45% of the S&amp;P 500 by market cap is set to report results next week, with other heavyweights including McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continued its upward trajectory on Friday, rising 2.7% following a massive 21% jump on Thursday — its biggest one-day gain since May 2013.
The S&amp;P 500 was up 0.5% at midday trading in New York, while the Nasdaq 100 surged by 1.5%, fueled by semiconductor stocks. 
The Dow Jones Industrial Average fell 0.3%, on track to end a six-week winning streak. The U.S. dollar strengthened further, with the DXY Index rising past the 104 mark, setting up for a fourth straight week of gains. Meanwhile, Treasury yields were steady. 
WTI crude rose 1.8%, driven by concerns over geopolitical tensions in the Middle East. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up slightly at $67,695.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,500.56</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,839.28</td>
<td>0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,219.60</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,271.11</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102225&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $582.19.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $423.18.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.3% to $498.83.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.2% up to $220.09.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 1.4%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) rallied 7% to levels last seen in October 2021 on better-than-expected quarterly results. </li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) rallied over 10% after reporting record new lease bookings. </li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), down 0.13%</li>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), down 1%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) up 7.6%, </li>
<li>Skechers U.S.A. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) down 0.2%, </li>
<li>Western Digital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 7.6%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), up 11%</li>
<li>Edward Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), down by 0.6%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 10%, </li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), up 6%, </li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), down 3.4%, </li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), up 6.7%, </li>
<li>Saia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>), up 9.2%. </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41549147/goldman-sachs-analyst-remains-bullish-on-boeing-despite-weak-q3-long-term-deep-valu">Goldman Sachs Analyst Remains Bullish On Boeing Despite Weak Q3: &#8216;Long-Term Deep-Value Opportunity</a>&#8216;</li>
</ul>
Photo: Shutterstock

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

DXCM

GOOG

GOOGL

MSFT

RIVN

SAIA

TSLA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?

On Tuesday, HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported third-quarter revenues of $17.49 billion, up 7.9% year-over-year, slightly missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $17.54 billion</a>.
The hospital chain reported adjusted EPS of $4.90, up from $3.91 a year ago, missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41541557/hca-healthcare-reports-third-quarter-2024-results" rel="noreferrer noopener">consensus of $4.96</a>.
In the third quarter of 2024, same-facility admissions increased 4.5% year over year, while same-facility equivalent admissions increased 4.5%.
Same-facility emergency room visits increased by 4.6%, same-facility inpatient surgeries increased by 1.6%, and same-facility outpatient surgeries declined by 2.0%.
Same facility revenue per equivalent admission increased by 2.5%.
For the third quarter of 2024, adjusted EBITDA totaled $3.27 billion, compared to $2.88 billion a year ago.
Guidance:&nbsp;HCA Healthcare reaffirmed its 2024 estimated guidance ranges. Given the ongoing impact of the two major hurricanes on the remainder of the year, the company estimates that results will likely be in the lower half of the ranges provided.
During its second-quarter earnings release, the company revised its fiscal year 2024 revenue guidance to $69.75 billion—$71.75 billion, compared to prior guidance of $67.75 billion—$70.25 billion and <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39913930/hospital-chain-operator-hca-healthcare-says-positive-q2-earnings-reflect-strong-demand-for-services" rel="noreferrer noopener">the consensus of&nbsp;$70.91 billion</a>.
The company forecasts 2024 EPS&nbsp;guidance&nbsp;of&nbsp;$21.60-22.80, up from the prior guidance of $19.70-$21.20&nbsp;and the consensus of&nbsp;$22.62.
The company expects 2024 adjusted EBITDA of $12.85 billion—$13.55 billion, versus the prior guidance of $13.75 billion—$14.25 billion.
During the fourth quarter of 2024, the company anticipates ongoing additional expenses and revenue losses due to Hurricane Helene's impact on its North Carolina facilities and Hurricane Milton, which impacted certain facilities in Florida during October, of approximately $200 to $300 million, or $0.60 to $0.90 per diluted share.
HCA Healthcare anticipates some ongoing impact in 2025 from Hurricane Helene on its North Carolina facilities.
The company believes these ongoing effects will be manageable and expects 2025 diluted EPS and Adjusted EBITDA growth to be near or slightly above the upper end of its long-term growth ranges.
Price Action:&nbsp;HCA Healthcare stock is down 8.95% at $363.19&nbsp;during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41542651/centene-says-it-is-positioned-to-capture-long-term-growth-in-government-sponsored-healthcare-lifts-" target="_blank" rel="noreferrer noopener">Centene Says It Is Positioned To Capture Long-Term Growth In Government-Sponsored Healthcare, Lifts Annual Outlook</a></li>
</ul>
Photo via Company

Guidance

Health Care

General

HCA Healthcare Q3 Earnings: Revenue And Profit miss, Sees Hurricane Impact on Q4 and FY25 Earnings Growth

WIIM

HCA Healthcare shares are trading lower after the company reported worse-than-expected Q3 financial results and announced it expects some ongoing impact in 2025 from Hurricane Helene.

The Company believes these ongoing effects will be manageable and currently expects 2025 diluted earnings per share and Adjusted EBITDA growth to be near, or slightly above, the upper end of its long-term growth ranges.

HCA Healthcare Anticipates Some Ongoing Impact In 2025 From Hurricane Helene On Its North Carolina Facilities

HCA Healthcare Q3 2024 Adj. EPS $4.90 Misses $4.96 Estimate, Sales $17.487B Miss $17.538B Estimate

Investors could see a second straight day of an opening in the green on Wall Street as the index futures point to a positive start on Friday. Treasury yields started cooling again after scaling three-month highs.
While Friday is a little light on the earnings side, consumer sentiment data and a speech by Boston Fed President Susan Collins could set the tone for the markets for the last day of the week.
All three major indices could close in the red for this week after surging for six consecutive weeks.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.27%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.26%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.23%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.56%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.30% to $580.95 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) surged 0.32% to $493.91, according to<a href="https://benzinga.grsm.io/lxquj26b2sag"> Benzinga Pro data</a>.
Cues From Last Session:
EV giant Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares witnessed their best single-day gain in over a decade after the Elon Musk-led EV giant blew past expectations.
A tightly packed week of earnings is now drawing to a close, with nearly a third of S&amp;P 500 companies having reported their results. According to FactSet data, more than 70% of these companies have managed to beat expectations in terms of profits.
The S&amp;P 500 ended its 3-day losing streak while the Nasdaq Composite maintained its momentum on the back of Tesla and other tech stocks.
On the economic data front, U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, industrials, and utilities stocks recording the biggest losses on Thursday. However, consumer discretionary and communication services stocks bucked the overall market trend, closing the session higher.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.76%</td>
<td>18,415.49</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.21%</td>
<td>5,809.86</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.33%</td>
<td>42,374.36</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.23%</td>
<td>2,218.92</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Following six consecutive weeks of gains, the markets have remained gloomy this week, with tech stocks offering some respite amid sideways movements in most other sectors.
Benchmark US 10-year treasury yields continued to cool down after scaling three-month highs.
On the economic data front, the S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September, while services PMI increased to 55.3 in October from 55.2 in the prior month.
"The election itself can be a bit of a hairy situation. I think right now, although the market sort of has been pricing in some Trump trades, I think the polls are still telling you that it&#8217;s a coin toss," Interactive Brokers chief strategist Steve Sosnick <a href="https://finance.yahoo.com/video/3-things-could-cause-market-213000687.html">said</a> in an interview with Market Domination.
On the other hand, despite the Tesla stock "firing on all cylinders" and turning positive year-to-date after Thursday's rally, fund manager Louis Navellier thinks the EV giant still <a href="https://investorplace.com/market360/2024/10/teslas-earnings-boost-stock-amid-robotaxi-innovations/">has</a> to improve its fundamentals before going long on the stock.
"Now is not a good time to buy Tesla. I would wait for its fundamentals to improve further before investing in the company."
See Also:<a href="https://www.benzinga.com/money/best-futures-trading-software"> Best Futures Trading Software</a>
Upcoming Economic Data:
<ul>
<li>Data on durable goods orders is scheduled to be released at 8:30 a.m. ET.</li>
<li>Data on consumer sentiment is scheduled to be released at 10 a.m. ET.</li>
<li>University of Michigan (UoM) is scheduled to release one and five-year inflation expectations at 10 a.m. ET.</li>
<li>Boston Fed President Susan Collins is scheduled to speak at 11 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Tesla will stay in focus after the stock registered its best single-day gains in over a decade, a day after beating margin and EPS estimates in its third-quarter earnings.</li>
<li>Capri Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) tumbled over 46% in premarket trading after a judge blocked its acquisition by fashion group Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>).</li>
<li>Spirit Airlines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) stock surged over 11% in premarket trading after the carrier announced the sale of 23 Airbus A320 aircraft worth $519 million. It also announced job cuts.</li>
</ul>
Investors are awaiting earnings results from&nbsp;AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>), Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), and HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) today.
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, surging nearly 0.7% as data showed a rise in spot demand.
The 10-year Treasury note yield eased marginally to 4.198%.
Asian markets were mixed on Thursday, with Chinese markets rising marginally while Japan's Nikkei 225 registering a decline.
European stocks remained tentative in early trading, concluding what has been a gloomy week so far.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41539590/tesla-shares-slip-in-pre-market-a-day-after-massive-22-rally-whats-going-on">Tesla Shares Slip In Pre-Market A Day After Massive 22% Rally: What&#8217;s Going On?</a></li>
</ul>
Photo courtesy: Shutterstock

Futures

Previews

Federal Reserve

CPRI

SAVE

US Stocks Set To Rise As Treasury Yields Ease, Tesla, Spirit Airlines Among Stocks In Focus: Fund Manager Says Despite Elon Musk's Company 'Firing On All Cylinders,' It's Still Not A 'Good Time To Buy'

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled mixed on Thursday, with the S&amp;P 500 recording its first positive session in a week.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) was the top-performing stock in the index. Shares of the company jumped around 22% on Thursday after reporting stronger-than-expected third-quarter earnings. International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) shares fell 6.2% following a third-quarter revenue miss.
On the economic data front, U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000. The S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September, while services PMI increased to 55.3 in October from 55.2 in the prior month.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, industrials, and utilities stocks recording the biggest losses on Thursday. However, consumer discretionary and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 141 points to 42,374.36 on Thursday. The S&amp;P 500 rose 0.21% to 5,809.86, while the Nasdaq Composite climbed 0.76% to close at 18,415.49 during Thursday's session.
Investors are awaiting earnings results from AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>), Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), and HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 63.4, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 62.3.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41516113/how-to-earn-500-a-month-from-weyerhaeuser-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Weyerhaeuser Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo courtesy: Shutterstock

S&P 500's 3-Day Losing Streak Ends Following Jump In Tesla Shares: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

With U.S. stock futures trading slightly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) to report quarterly earnings at $4.38 per share on revenue of $6.71 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. AutoNation shares gained 0.4% to $163.81 in after-hours trading.</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) reported better-than-expected third-quarter results.&nbsp; The company reported quarterly earnings of $4.51 per share, which beat the analyst consensus estimate of $3.76. Quarterly revenue came in at $10.014 billion, which beat the analyst consensus estimate of $9.861 billion. Capital One Financial shares climbed 4.9% to $160.71 in the after-hours trading session.</li>
<li>Analysts are expecting Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) to post quarterly earnings at 89 cents per share on revenue of $5.00 billion. The company will release earnings before the markets open. Colgate-Palmolive shares gained 0.7% to $100.40 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) reported better-than-expected earnings for the third quarter, while sales missed estimates. Edwards Lifesciences shares fell 4.4% to $67.25 in the after-hours trading session.</li>
<li>Analysts expect HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) to report quarterly earnings at $4.96 per share on revenue of $17.54 billion before the opening bell. HCA Healthcare shares fell 1% to $395.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41516113/how-to-earn-500-a-month-from-weyerhaeuser-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Weyerhaeuser Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo courtesy: AutoNation

AutoNation, Capital One Financial And 3 Stocks To Watch Heading Into Friday

Deep-pocketed investors have adopted a bearish approach towards HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HCA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 30 extraordinary options activities for HCA Healthcare. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 60% bearish. Among these notable options, 13 are puts, totaling $584,901, and 17 are calls, amounting to $1,026,933.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $430.0 for HCA Healthcare over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for HCA Healthcare's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of HCA Healthcare's whale activity within a strike price range from $120.0 to $430.0 in the last 30 days. 
<h3>HCA Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729798233_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$8.1</td>
<td>$7.1</td>
<td>$7.3</td>
<td>$430.00</td>
<td>$219.0K</td>
<td style="text-align: right;">314</td>
<td style="text-align: right;">308</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.6</td>
<td>$15.2</td>
<td>$15.2</td>
<td>$390.00</td>
<td>$118.5K</td>
<td style="text-align: right;">215</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$104.6</td>
<td>$99.6</td>
<td>$104.6</td>
<td>$310.00</td>
<td>$104.6K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$25.5</td>
<td>$24.1</td>
<td>$25.5</td>
<td>$390.00</td>
<td>$99.4K</td>
<td style="text-align: right;">113</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$15.3</td>
<td>$14.3</td>
<td>$15.3</td>
<td>$410.00</td>
<td>$71.9K</td>
<td style="text-align: right;">505</td>
<td style="text-align: right;">276</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
After a thorough review of the options trading surrounding HCA Healthcare, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of HCA Healthcare</h3>
<ul>
<li>Currently trading with a volume of 1,490,984, the HCA's price is down by -1.26%, now at $404.88. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About HCA Healthcare</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $413.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for HCA Healthcare, targeting a price of $395. 
&#x2A; In a cautious move, an analyst from Keybanc downgraded its rating to Overweight, setting a price target of $475. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $392. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $392. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for HCA Healthcare with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Check Out What Whales Are Doing With HCA

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is preparing to release its quarterly earnings on Friday, 2024-10-25. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect HCA Healthcare to report an earnings per share (EPS) of $4.96.
HCA Healthcare bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.62, leading to a 1.11% increase in the share price on the subsequent day.
Here's a look at HCA Healthcare's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>4.88</td>
<td>5.01</td>
<td>5.04</td>
<td>3.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.50</td>
<td>5.36</td>
<td>5.90</td>
<td>3.91</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729778509_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of HCA Healthcare were trading at $410.03 as of October 23. Over the last 52-week period, shares are up 79.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HCA/earnings">To track all earnings releases for HCA Healthcare visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For HCA Healthcare

In the current market session, HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock price is at $409.29, after a 0.36% drop. However, over the past month, the company's stock increased by 1.86%, and in the past year, by 81.62%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729626385_0.png" alt="Past Year Chart" />

<h3>A Look at HCA Healthcare P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
HCA Healthcare has a lower P/E than the aggregate P/E of 32.47 of the Health Care Providers &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729626385_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for HCA Healthcare

Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Equal-Weight and raises the price target from $365 to $395.

Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $395

The United States is facing a significant shortage of intravenous (IV) fluids, including saline and dextrose solutions, exacerbated by damage to Baxter International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) plants in North Carolina <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41340376/baxters-north-carolina-plant-recovery-underway-after-hurricane-flooding-starts-product-imports" rel="noreferrer noopener">due to Hurricane Helene</a>.
These essential fluids, already in limited supply before the hurricane, are critical for various medical treatments, such as hydration, wound cleaning, and dialysis.
The closure of Baxter&#8217;s plant, which produces about 60% of the country&#8217;s IV fluids, has intensified the scarcity, leaving hospitals struggling to <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41257734/baxters-north-carolina-facility-manufactures-60-of-iv-fluids-and-peritoneal-dialysis-solutions-s" rel="noreferrer noopener">maintain adequate supplies</a>.
An NBC <a href="https://www.nbcnews.com/health/health-news/long-helene-iv-fluid-shortages-plagued-hospitals-rcna175563">report </a>noted that years before the hurricane, the U.S. was already experiencing shortages of IV fluids, according to the FDA.
Saline solution has been in short supply since 2018, sterile water since 2021, and dextrose solution since early 2022.
The hurricane worsened the situation, adding lactated Ringer&#8217;s solution and peritoneal dialysis fluids to the list of shortages.
This shortage is a critical issue as hospitals depend on these fluids for life-saving treatments, and they are challenging to produce due to high regulatory standards and the delicate sterilization process involved.
Erin Fox, senior pharmacy director at the University of Utah Health, told NBC that the low profitability of manufacturing these fluids has deterred companies from entering the market.
IV fluids require significant space and resources to produce and store, and their relatively low cost creates little financial incentive for drugmakers.
Speaking to NBC, Michael Ganio, senior director of pharmacy practice at the American Society of Health-System Pharmacists, added that controlling endotoxins, harmful bacteria resistant to sterilization, further complicates the production process.
In response to the crisis, the federal government has invoked the Defense Production Act, enabling Baxter to secure priority access to materials necessary to rebuild its North Carolina facility.
The FDA has also allowed Baxter to temporarily import IV fluids from plants in Canada, China, Ireland, and the U.K. Despite these efforts, Baxter expects to meet only 90% of its customers&#8217; needs by the end of the year.
The shortage affects hospitals, with many postponing elective surgeries due to insufficient IV fluid supplies.
Citing some analysts, Reuters highlighted that the impact on medical device manufacturers, such as Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) and Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), will be minimal if the shortage is resolved by early next year.
However, the situation remains concerning for hospital operators like HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), as delays in surgeries could affect their revenues.
Baxter <a target="_blank" href="https://www.baxter.com/baxter-newsroom/hurricane-helene-updates" rel="noreferrer noopener">announced</a> that the first FDA-authorized product shipments for temporary importation are set to arrive in the U.S. this weekend.
In collaboration with the ASPR, the company estimates that by year-end, about 200 Boeing 747 cargo planes—equivalent to nearly 18,000 tons of product—will be delivered from Europe and Asia.
Providers could begin receiving these shipments in the coming weeks.
Price Action: Shares of BAX were up 0.02% at $36.66 at the time of publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41401926/aura-biosciences-bladder-cancer-candidate-demonstrates-tumor-shrinkage-in-patients-with-high-grad" target="_blank" rel="noreferrer noopener">Aura Biosciences&#8217; Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease</a>.</li>
</ul>
Photo: SeventyFour/Shutterstock.com

US Hospitals Face Critical IV Fluid Shortage After Baxter Facility Shuts Down Due To Hurricane Helene

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 5 years by 12.54% on an annualized basis producing an average annual return of 26.8%. Currently, HCA Healthcare has a market capitalization of $105.96 billion. 
Buying $1000 In HCA: If an investor had bought $1000 of HCA stock 5 years ago, it would be worth $3,321.50 today based on a price of $410.57 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729108920_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,300 Today

Investors with a lot of money to spend have taken a bearish stance on HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HCA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for HCA Healthcare.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 60%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $29,255, and 9, calls, for a total amount of $520,072.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $390.0 to $405.0 for HCA Healthcare over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for HCA Healthcare's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across HCA Healthcare's significant trades, within a strike price range of $390.0 to $405.0, over the past month.
<h3>HCA Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728931528_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.9</td>
<td>$5.3</td>
<td>$5.9</td>
<td>$395.00</td>
<td>$145.7K</td>
<td style="text-align: right;">279</td>
<td style="text-align: right;">252</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$14.6</td>
<td>$13.9</td>
<td>$14.4</td>
<td>$405.00</td>
<td>$96.5K</td>
<td style="text-align: right;">65</td>
<td style="text-align: right;">146</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$14.5</td>
<td>$14.2</td>
<td>$14.2</td>
<td>$405.00</td>
<td>$68.1K</td>
<td style="text-align: right;">65</td>
<td style="text-align: right;">249</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$14.3</td>
<td>$14.1</td>
<td>$14.1</td>
<td>$405.00</td>
<td>$43.7K</td>
<td style="text-align: right;">65</td>
<td style="text-align: right;">66</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$400.00</td>
<td>$38.1K</td>
<td style="text-align: right;">256</td>
<td style="text-align: right;">182</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
In light of the recent options history for HCA Healthcare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>HCA Healthcare's Current Market Status</h3>
<ul>
<li>With a volume of 353,681, the price of HCA is up 0.54% at $396.68. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<h3>Expert Opinions on HCA Healthcare</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $419.6666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $392. 
&#x2A; In a cautious move, an analyst from Keybanc downgraded its rating to Overweight, setting a price target of $475. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $392. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for HCA Healthcare, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

HCA Healthcare's Options: A Look at What the Big Money is Thinking

Morgan Stanley analyst Craig Hettenbach has maintained their neutral stance on HCA stock, giving a Hold rating yesterday. Craig Hettenbach gave his...

HCA Healthcare: Hold Recommendation Amid Modest Misses and External Challenges

Analyst Ryan Langston from TD Cowen maintained a Buy rating on HCA Healthcare (HCA – Research Report) and decreased the price target to $440.00 fro...

Promising Outlook for HCA Healthcare: Strong Fundamentals and Strategic Management Support Buy Rating

Analysts have been eager to weigh in on the Healthcare sector with new ratings on HCA Healthcare (HCA – Research Report), Viatris (VTRS – Research ...

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Viatris (VTRS) and Syndax Pharmaceuticals (SNDX)

Morgan Stanley lowered the firm's price target on HCA Healthcare (HCA) to $406 from $427 and keeps an Equal Weight rating on the shares. While the ...

HCA Healthcare price target lowered to $406 from $427 at Morgan Stanley

TD Cowen analyst Gary Taylor lowered the firm's price target on HCA Healthcare (HCA) to $440 from $450 and keeps a Buy rating on the shares. The fi...

HCA Healthcare price target lowered to $440 from $450 at TD Cowen

Truist Financial analyst David S Macdonald reiterated a Buy rating on HCA Healthcare (HCA – Research Report) today. The company's shares closed las...

HCA Healthcare (HCA) Receives a Buy from Truist Financial

In a report released today, Whit Mayo from Leerink Partners reiterated a Buy rating on HCA Healthcare (HCA – Research Report), with a price target ...

HCA Healthcare: Strong Buy Rating Despite External Challenges and Positive Long-term Outlook

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on HCA Healthcare (HCA – Research Report) today and set a price target of $400.00. T...

HCA Healthcare (HCA) Receives a Rating Update from a Top Analyst

Oppenheimer raised the firm's price target on HCA Healthcare (HCA) to $400 from $390 and keeps an Outperform rating on the shares. The firm notes H...

Comments

HCA Healthcare

HCA Healthcare (HCA) Opciones

HCA Healthcare (NYSE:HCA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL